Theriva Biologics, Inc. TOVX

Theriva Biologics, Inc. reported second quarter 2026 operational highlights and financial results. Quarterly results provide standard performance data with limited trajectory shift.

Theriva Biologics, Inc. reported its Q2 earnings, highlighting key financial metrics and operational updates. The company continues to focus on its therapeutic developments and strategic initiatives aimed at enhancing its market position. Investors are keenly observing the implications of these results on future growth prospects. The earnings report indicates moderate financial performance and operational updates that may influence investor sentiment and future strategies.

Theriva Biologics, Inc. (TOVX) reported its operational highlights and financial results for the second quarter of 2025, showcasing advancements in its clinical programs and financial performance. The company emphasized progress in its therapeutic pipeline and strategic initiatives aimed at enhancing shareholder value. Key metrics included revenue figures and updates on ongoing trials, reflecting a commitment to innovation and growth in the biopharmaceutical sector. The reported operational highlights and financial results indicate moderate progress in key areas that could influence the company's performance.

Theriva Biologics dosed the first patient in its VIRAGE2 Phase 2a trial testing more frequent dosing of VCN-01 for first-line metastatic pancreatic ductal adenocarcinoma. First patient dosing advances Phase 2a evaluation of VCN-01 dosing regimen in pancreatic cancer.

Theriva Biologics obtains regulatory authorization to initiate VIRAGE2 Phase 2a trial evaluating more frequent VCN-01 dosing in first-line metastatic pancreatic ductal adenocarcinoma patients. Phase 2a trial authorization advances VCN-01 development in pancreatic cancer and strengthens Theriva pipeline momentum.

Theriva Biologics announced publication of VCN-01 Phase 1 clinical trial results in head and neck cancer patients in Clinical Cancer Research. Phase 1 data publication for VCN-01 provides moderate validation for pipeline progress without altering near-term financial trajectory.

Theriva Biologics reports first quarter 2026 operational highlights and financial results. Quarterly operational highlights and financial results affect key financial performance metrics and investor sentiment.

Theriva Biologics announces upcoming presentation of additional data from the VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic cancer at the AACR 2026 Annual Meeting. Upcoming presentation of additional Phase 2b data at a major oncology conference highlights pipeline progress but lacks immediate transformative results.

Theriva Biologics announced positive feedback from U.S. FDA End-of-Phase 2 meeting, endorsing the design of a Phase 3 trial for VCN-01 combined with gemcitabine/nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma. FDA endorsement of Phase 3 trial design for VCN-01 represents a major regulatory milestone advancing Theriva's lead oncology asset toward potential approval.

Theriva Biologics, Inc. (TOVX) reported full-year 2025 operational highlights and financial results. Full-year financial results and operational highlights represent major disclosures that can significantly alter investor sentiment and stock trajectory.

Theriva Biologics licensed its SYN-020 to Rasayana Therapeutics for development across multiple indications, potentially generating upfront payments, milestones, and royalties. Licensing SYN-020 outgenerates revenue streams via milestones and royalties while offloading development costs, marking a significant strategic pivot for Theriva.

Theriva Biologics, Inc. (TOVX) announced that data from its VCN-01 retinoblastoma Phase 1 clinical trial will be presented at the upcoming Asia-Pacific Academy of Ophthalmology (APAO) 2026 conference. This presentation is expected to highlight the potential of VCN-01 as a treatment option for retinoblastoma, a rare pediatric eye cancer, and may attract attention from the medical community and investors. The presentation of clinical trial data at a major conference could significantly influence investor sentiment and the company's future trajectory.

Theriva Biologics, Inc. has received scientific advice from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding the design of its Phase 3 clinical trial for VCN-01, an oncolytic virus therapy aimed at treating patients with advanced solid tumors. The guidance is expected to help refine the trial's objectives and endpoints, potentially enhancing the drug's development pathway and regulatory approval prospects. The CHMP's scientific advice is a significant step that could influence the regulatory approval process and market positioning of VCN-01.

Theriva Biologics, Inc. announced that it received positive scientific advice from the European Medicines Agency (EMA) regarding the design of a Phase 3 trial for VCN-01, a treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). This guidance is expected to support the advancement of the trial, which aims to evaluate the efficacy and safety of VCN-01 in patients with this aggressive form of cancer. Positive EMA advice is likely to significantly impact the company's future performance and investor sentiment regarding VCN-01's development.

Theriva Biologics, Inc. reported its Q3 earnings, highlighting key financial metrics and operational updates. The company continues to focus on its therapeutic developments and strategic initiatives aimed at enhancing its market position. Investors are keenly observing the implications of these results on future growth prospects. Q3 earnings reveal important financial performance indicators that may influence investor sentiment and operational strategies.

Theriva Biologics, Inc. (TOVX) reported its operational highlights and financial results for the third quarter of 2025, showcasing advancements in its clinical programs and financial metrics. The company emphasized progress in its pipeline, including updates on ongoing trials and collaborations. Financial results indicated changes in revenue and expenditures, reflecting the company's strategic focus on development and commercialization efforts. Overall, the report underscores Theriva's commitment to innovation in the biopharmaceutical sector. The operational highlights and financial results indicate moderate progress in key areas that could influence future performance.

Theriva Biologics, Inc. (TOVX) has announced a warrant inducement transaction that is expected to generate $4.0 million in gross proceeds. This move aims to strengthen the company's financial position and support its ongoing development efforts. The warrant inducement transaction is expected to provide additional funding, which may moderately influence the company's financial performance and operational capabilities.

Theriva Biologics, Inc. (TOVX) announced upcoming presentations at various medical meetings, highlighting its commitment to advancing its therapeutic programs and engaging with the medical community. These presentations are expected to showcase the company's innovative approaches and research findings, potentially enhancing its visibility and collaboration opportunities within the industry. Upcoming presentations may positively influence investor sentiment and collaboration opportunities, but the overall impact on the company's trajectory is expected to be limited.

Theriva Biologics, Inc. announced the presentation of its next-generation oncolytic adenovirus, VCN-12, at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT). This presentation highlights the advancements in their therapeutic approach to cancer treatment, showcasing the potential of VCN-12 in enhancing efficacy and safety in oncolytic virotherapy. The presentation of VCN-12 at a prominent conference indicates significant advancements in Theriva's product pipeline, which could enhance its competitive positioning and investor sentiment.

Theriva Biologics, Inc. announced the presentation of data from its Phase 1 clinical trial of VCN-01 for refractory retinoblastoma at the ASCO Annual Meeting on May 31, 2025. The trial, conducted at Sant Joan de Déu Barcelona Children’s Hospital, evaluated the safety and tolerability of VCN-01 in patients for whom other treatments were ineffective. Additionally, Theriva's management will attend an off-site meeting to discuss topline results from the VIRAGE Phase 2b trial of VCN-01 in metastatic pancreatic cancer. VCN-01 is an oncolytic adenovirus designed to selectively target tumor cells and improve treatment outcomes. The company holds various designations for VCN-01 from regulatory agencies for its potential in treating both retinoblastoma and pancreatic cancer. The presentation of clinical trial data and ongoing discussions for a Phase 3 trial could significantly influence Theriva's market position and investor sentiment.

Theriva Biologics, Inc. reported that its VCN-01 treatment achieved primary efficacy and safety endpoints in the VIRAGE Phase 2b trial for metastatic pancreatic ductal adenocarcinoma. The company closed a public offering on May 8, 2025, raising approximately $7.5 million to extend its cash runway into early 2026. Financial results for Q1 2025 showed decreased general and administrative expenses and research and development costs, with a net loss of $4.3 million. Cash and cash equivalents totaled $10 million as of March 31, 2025, increasing to $14.1 million post-offering. Theriva is scaling up manufacturing for VCN-01 and finalizing plans for a Phase 3 trial. The successful trial results and funding for further development of VCN-01 are likely to significantly impact Theriva's future performance and market position.

Theriva Biologics, Inc. (TOVX) reported its Q1 earnings, highlighting key financial metrics and operational updates. The company continues to focus on its therapeutic pipeline and strategic initiatives aimed at enhancing shareholder value. Despite challenges in the market, Theriva remains committed to advancing its projects and addressing investor concerns. The earnings report indicates ongoing operational focus and potential for moderate financial impact.

Theriva Biologics, Inc. (TOVX) has closed a public offering of 6,818,180 shares of common stock and warrants, raising approximately $7.5 million. The offering price was set at $1.10 per share and warrant. Proceeds will primarily be used for working capital, research and development, and potential investments in other products or technologies. A.G.P./Alliance Global Partners served as the sole placement agent. The offering was conducted under a registration statement filed with the SEC, which became effective on May 7, 2025. The capital raised will support ongoing research and development efforts, potentially influencing future product innovation.

Theriva Biologics, Inc. announced positive topline results from the VIRAGE Phase 2b clinical trial of VCN-01 combined with gemcitabine/nab-paclitaxel for newly-diagnosed metastatic pancreatic cancer patients. Patients receiving VCN-01 showed improved overall survival (10.8 months vs. 8.6 months), progression-free survival, and duration of response compared to the standard treatment alone. VCN-01 was well-tolerated with manageable adverse events. The trial's findings suggest that additional doses of VCN-01 may enhance treatment benefits. A webinar featuring key opinion leaders will discuss the data on May 7, 2025. The trial results indicate a significant potential for VCN-01 to improve treatment outcomes in a high-unmet medical need area, likely influencing future strategic decisions and investor sentiment.

Theriva Biologics, Inc. (TOVX) announced a public offering priced at $1.10 per share, aiming to raise approximately $7.5 million. The offering includes 6,818,180 shares and warrants, with proceeds intended for working capital, research and development, and potential investments in other products or technologies. The closing is expected on May 8, 2025, pending customary conditions. A.G.P./Alliance Global Partners is the placement agent for the offering. The public offering may provide necessary funding for research and development, impacting financial performance and product innovation.

Theriva Biologics, Inc. announced the presentation of interim blinded safety and pharmacokinetic data from its Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients at the ESCMID Global Congress in Vienna. The trial aims to evaluate the safety and tolerability of SYN-004, which is designed to prevent acute graft-versus-host-disease (aGVHD) by degrading certain IV beta-lactam antibiotics in the gastrointestinal tract. The study is expected to enroll up to 36 participants across three cohorts, each receiving different antibiotics. The findings may provide insights into the protective effects of SYN-004 on the gut microbiome and patient outcomes. The presentation of safety and pharmacokinetic data from a significant clinical trial could lead to major strategic moves and influence investor sentiment.

Theriva Biologics, Inc. announced positive outcomes from the second Independent Data Monitoring Committee (IDMC) review of its VIRAGE Phase 2b clinical trial for VCN-01 in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC). The IDMC found VCN-01 to be well tolerated among 101 patients, with adverse events consistent with prior trials. The trial, which completed patient enrollment in September 2024, anticipates topline clinical outcomes data in Q2 2025. CEO Steven A. Shallcross emphasized the importance of these findings for potential Phase 3 trial discussions with regulatory agencies later this year. Positive safety data from a larger patient cohort supports the feasibility of VCN-01, potentially influencing future regulatory discussions and trial designs.

Theriva Biologics, Inc. (NYSE American: TOVX) will present at the NeauxCancer 2025 Conference from March 27th-29th, 2025, at The Roosevelt New Orleans Hotel. The company's presentation is scheduled for March 28th at 9:00am during the Innovation track, which highlights emerging biotech and healthcare companies. Theriva's management will also be available for one-on-one meetings with interested investors. The company is focused on developing therapeutics for cancer and related diseases, including its lead candidates VCN-01, SYN-004, and SYN-020. The conference presentation may enhance visibility and investor interest, potentially influencing future financial performance and product innovation.

Theriva Biologics, Inc. announced the completion of enrollment in the VIRAGE Phase 2b trial for VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC), with topline data expected in Q2 2025. The FDA granted Fast Track and Rare Pediatric Disease designations for VCN-01, and guidance was received from the FDA and EMA for a potential Phase 3 trial. As of December 31, 2024, the company reported $11.6 million in cash, providing a runway into Q3 2025. General and administrative expenses increased slightly, while research and development expenses decreased due to lower clinical trial costs. The company also recognized a tax credit of $1.8 million from the Spanish government for R&D efforts. The completion of the Phase 2b trial and regulatory designations significantly enhance the company's prospects for VCN-01 in treating PDAC and retinoblastoma.

Theriva Biologics announces FDA guidance on Phase 3 study of VCN-01 for metastatic pancreatic cancer. The FDA guidance on the Phase 3 study of VCN-01 for metastatic pancreatic cancer could significantly impact Theriva Biologics' future and market performance.